Inhibition of murine AIDS by alternate administration of azidothymidine and fludarabine monophosphate

Journal of Acquired Immune Deficiency Syndromes

Volumn 23, Issue 3, 2000, Pages 209-220

  Fraternale, A ^a   Casabianca, A ^a   Tonelli, A ^a   Vallanti, G ^a   Chiarantini, L ^a   Brandi, G ^b   Celeste, A G ^b   Magnani, M ^b  

^a Giorgio Fornaini Inst Biologic C   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

2 Fluoroara AMP (fludarabine); AZT; Murine retrovirus induced immunodeficiency

Indexed keywords

FLUDARABINE PHOSPHATE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; LYMPHOCYTE COUNT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; RODENT DISEASE; SPLENOMEGALY; VIREMIA;

EID: 0034163136     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-200003010-00001     Document Type: Article

References (42)

1. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N Engl J Med 1996;334:1011-8.
2. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
4. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-91.
5. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-13.
6. Roberts NA. Drug-resistance patterns of saquinavir and other HIV protease inhibitors. AIDS 1995;9:S27-32.
7. Boucher C. Rational approaches to resistance: using saquinavir. AIDS 1996;10:S15-19.
8. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-71.
9. Finzi D, Silliciano RF. Viral Dynamics in HIV-1 infection. Cell 1998;93:665-71.
10. Gartner S, Markovits P, Markovits DM, Kaplan MH, Gallo RC, Popovic M. The role of mononuclear phagocytes in HTLV-III/ LAV infection. Science 1986;233:215-19.
11. Ho DD, Rota TR, Hirsch MS. Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest 1986;77: 1712-15.
12. Schnittman SM, Psallidopoulos MC, Lane HC, et al. The reservoir for HIV-1 in human peripheral blood is a T cell that maintains expression of CD4. Science 1989;245:305-8.
13. + T cells. Science 1992;257:383-7.
14. Pope M, Betjes MG, Romani N, et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 1994;78:389-98.
15. Chen CH, Cheng YC. The role of cytoplasmic deoxycytidine kinase in the mitochondrial effects of the anti-human immunodeficiency virus compound, 2′, 3′-dideoxycytidine. J Biol Chem 1992; 267:2856-9.
16. Gao WY, Agbaria R, Driscoll JS, Mitsuya H. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′, 3′-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem 1994;269:12633-8.
17. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-9.
18. Lipsky JJ. Abnormal fat accumulation in patients with HIV-1 infection. Lancet 1998;351:847-8.
19. D'Arminio MA, Testa L, Adorni F, et al. Clinical outcome and predictive factors of failure of highly active antiretroviral therapy in antiretroviral-experienced patients in advanced stages of HIV-1 infection. AIDS 1998;12:1631-7.
20. Morse HC III, Chattopadhyay SK, Makino M, Fredrickson TN, Hügin AW, Hartley JW. Retrovirus-induced immunodeficiency in the mouse: MAIDS as a model of AIDS. AIDS 1992;6:607-21.
21. Jolicoeur P. The murine acquired immunodeficiency syndrome (MAIDS): an animal model to study the AIDS pathogenesis. FASEB J 1991;5:2398-405.
22. Morse HC III, Giese N, Morawetz R, et al. Cells and cytokines in the pathogenesis of MAIDS, a retrovirus-induced immunodeficiency syndrome of mice. Springer Semin Immunopathol 1995;17: 231-45.
23. Redman JR, Cabanillas F, Velasquez WS, et al. Phase II trial of Fludarabine phosphate in lymphoma: an effective new agent in low grade lymphoma. J Clin Oncol 1992;10:790-4.
24. Hochster H, Cassileth P. Fludarabine phosphate therapy of non-Hodgkin's lymphoma. Semin Oncol 1990;17:S63-5.
25. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ. Activity of Fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst 1990;82:1353-5.
26. Keating MJ, McLaughlin P, Plunkett W, et al. Fludarabine - present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol 1994;5:S79-83.
27. Plunkett W, Gandhi V, Huang P, et al. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol 1993;20:S2-12.
28. Mosier DE, Yetter RA, Morse HCIII. Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS). J Exp Med 1987;165:1737-42.
29. Fraternale A, Tonelli A, Casabianca A, et al. Role of macrophage protection in the development of murine AIDS. JAIDS J Acquir Immune Defic Syndr 1999;21:81-9.
30. Palamara AT, Garaci E, Rotilio G, et al. Inhibition of murine AIDS by reduced glutathione. AIDS Res Hum Retroviruses 1996;12: 1373-81.
31. Casabianca A, Vallanti G, Magnani M. Competitive PCR for quantification of BM5d proviral DNA in mice with AIDS. J Clin Microbiol 1998;36:2371-4.
32. Fraternale A, Casabianca A, Rossi L, et al. Inhibition of murine AIDS by combination of AZT and dideoxycytidine-5′-triphosphate. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:164-73.
33. Rossi L, Brandi G, Schiavano GF, Chiarantini L, Albano A, Magnani M. In vitro and in vivo toxicity of 2′, 3′-dideoxycytidine in mice. Chem Biol Inter 1992;85:255-63.
34. Keating MJ, Kantarjian H, Talpaz M, et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood 1989;74:19-25.
35. Balzarini J, Pauwels R, Baba M, et al. The in vitro and in vivo anti-retrovirus activity, and intracellular metabolism of 3′-azido-2′, 3′-dideoxythymidine and 2′, 3′-dideoxycytidine are highly dependent on the cell species. Biochem Pharmacol 1988;37:893-903.
36. Basham T, Rios CD, Holdener T, Merigan TC. Zidovudine (AZT) reduces virus titer, retards immune dysfunction, and prolongs survival in the LP-BM5 murine induced immunodeficiency model. J Infect Dis 1990;161:1006-9.
37. Chun TW, Carruth L, Finzi D, et al. Quantitation of latent tissue reservoirs and total body load in HIV-1 infection. Nature 1997; 387:183-8.
38. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with Fludarabine monophosphate. Eur J Haematol 1993;50:292-6.
39. Lori F, Jessen H, Lieberman J, Clerici M, Tinelli C, Lisziewicz J. Immune restoration by combination of a cytostatic drug (hydroxyurea) and anti-HIV drugs (didanosine and indinavir). AIDS Res Hum Retroviruses 1999;15:619-24.
40. Raez L, Cabrai L, Cai JP, et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 1999;15:713-9.
41. Scadden DT, Schenkein DP, Bernstein Z, et al. Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma. Cancer 1998;83:2580-7.
42. Edison J, Jost J, Ledergerber B, Jost L, Strasser F, Weber R. HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy. AIDS 1999;13:732-4.